Market Overview:
The global hospital acquired infection control market is expected to grow at a CAGR of 7.5% from 2018 to 2030. The growth in the market can be attributed to the increasing incidence of hospital-acquired infections (HAIs), growing awareness about HAIs, and rising demand for advanced infection control products and services. Based on type, the global hospital acquired infection control market is segmented into catheter-associated urinary tract infections (CAUTIs), surgical site infections (SSIs), central line-associated bloodstream infections (CLABSIs), and respiratory infections. CAUTI is further segmented into urinary tract infection caused by Escherichia coli (E. coli) and other pathogens. SSI is further classified into superficial incisional SSI, deep incisional SSI, organ/space SSI, and implantable device-related SSI. CLABSI is further divided into primary CLABSI and recurrent CLABSIS . Respiratory Infection includes pneumonia, tuberculosis ,and viral respiratory illnesses such as human metapneumovirus (HMPV) . Based on application, the global hospital acquired infection control market is segmented into hospitals & ICUs , outpatient care centers , long-term care facilities(LTCFs) .
Product Definition:
Hospital-acquired infection control is the practice of preventing and controlling infections that occur in patients during their hospital stay. Hospital-acquired infections can cause serious illness and even death, so it is important to have effective infection control procedures in place.
Catheter-associated Urinary Tract Infections (CAUTIs):
CAUTIs are also known as catheter-associated urinary tract infections. It is a type of Hospital Acquired Infection (HAI). The infection can occur in the urethra, bladder or kidney and it's majorly due to over usage of catheters.
Surgical Site Infections (SSIs):
Hospital-acquired infections (HAIs) are nosocomial infections that occur as a result of medical treatment at hospitals. The most common types of HAIs include urinary tract infection, pneumonia, surgical site infection and bloodstream infection. Surgical site infections are the most serious type of HAI which occurs during surgery or other medical procedure and affects mainly the deep tissues.
Application Insights:
The hospitals and ICUs segment dominated the global hospital acquired infection control market in 2017. This is attributed to a large number of healthcare facilities and high prevalence of diseases that lead to improper hygiene, such as catheter-associated urinary tract infections (CAUTIs) & surgical site infections (SSIs). According to a study published by NCBI, around 1.3 million CAUTI cases are reported every year globally. Furthermore, according to the CDC approximately 647 thousand women get SSI annually in U.S., out of which about 1010 SSIs are reported due to catheters/catheter-related devices each year in U.S., resulting in substantial growth opportunities for this segment over the forecast period for hospitals and ICUs worldwide.
Regional Analysis:
North America dominated the global hospital acquired infection control market in 2017. This can be attributed to the presence of a large number of hospitals and healthcare organizations that are actively involved in improving their infection control programs. The U.S.
Asia Pacific is expected to grow at a lucrative CAGR over the forecast period owing to rising medical tourism coupled with government initiatives for building world-class hospitals & clinics in emerging economies such as India & China. Furthermore, growing awareness regarding HAICs among patients and physicians will drive this regional market further.
Growth Factors:
- Increasing incidence of hospital acquired infections (HAIs)
- Rising demand for HAI prevention and control measures
- Growing awareness about hospital acquired infections and their prevention methods
- Proliferation of new technologies for the diagnosis and treatment of hospital acquired infections
- Stringent government regulations to prevent the spread of hospital acquired infections
Scope Of The Report
Report Attributes
Report Details
Report Title
Hospital Acquired Infection Control Market Research Report
By Type
Catheter-associated Urinary Tract Infections (CAUTIs), Surgical Site Infections (SSIs), Central Line-associated Bloodstream Infections (CLABSIs), Respiratory Infections
By Application
Hospitals and ICUs, Outpatient Care Centers, Long-term Care Facilities (LTCFs)
By Companies
Pfizer, Roche, Merck, Johnson & Johnson, Abott, Bayer, BD, Kimberly-Clark, Nordion, Cepheid, Pfizer
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
235
Number of Tables & Figures
165
Customization Available
Yes, the report can be customized as per your need.
Global Hospital Acquired Infection Control Market Report Segments:
The global Hospital Acquired Infection Control market is segmented on the basis of:
Types
Catheter-associated Urinary Tract Infections (CAUTIs), Surgical Site Infections (SSIs), Central Line-associated Bloodstream Infections (CLABSIs), Respiratory Infections
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals and ICUs, Outpatient Care Centers, Long-term Care Facilities (LTCFs)
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Pfizer
- Roche
- Merck
- Johnson & Johnson
- Abott
- Bayer
- BD
- Kimberly-Clark
- Nordion
- Cepheid
- Pfizer
Highlights of The Hospital Acquired Infection Control Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Catheter-associated Urinary Tract Infections (CAUTIs)
- Surgical Site Infections (SSIs)
- Central Line-associated Bloodstream Infections (CLABSIs)
- Respiratory Infections
- By Application:
- Hospitals and ICUs
- Outpatient Care Centers
- Long-term Care Facilities (LTCFs)
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Hospital Acquired Infection Control Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Hospital acquired infection control is the practice of preventing and controlling infections in hospitals. Infection control includes measures to prevent the spread of infection, such as cleaning and disinfecting surfaces, using effective hygiene practices, and monitoring patients for signs of illness. Hospital acquired infection control also includes treating any infections that do occur.
Some of the key players operating in the hospital acquired infection control market are Pfizer, Roche, Merck, Johnson & Johnson, Abott, Bayer, BD, Kimberly-Clark, Nordion, Cepheid, Pfizer.
The hospital acquired infection control market is expected to grow at a compound annual growth rate of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Hospital Acquired Infection Control Market Overview 4.1 Introduction 4.1.1 Market Taxonomy 4.1.2 Market Definition 4.1.3 Macro-Economic Factors Impacting the Market Growth 4.2 Hospital Acquired Infection Control Market Dynamics 4.2.1 Market Drivers 4.2.2 Market Restraints 4.2.3 Market Opportunity 4.3 Hospital Acquired Infection Control Market - Supply Chain Analysis 4.3.1 List of Key Suppliers 4.3.2 List of Key Distributors 4.3.3 List of Key Consumers 4.4 Key Forces Shaping the Hospital Acquired Infection Control Market 4.4.1 Bargaining Power of Suppliers 4.4.2 Bargaining Power of Buyers 4.4.3 Threat of Substitution 4.4.4 Threat of New Entrants 4.4.5 Competitive Rivalry 4.5 Global Hospital Acquired Infection Control Market Size & Forecast, 2020-2028 4.5.1 Hospital Acquired Infection Control Market Size and Y-o-Y Growth 4.5.2 Hospital Acquired Infection Control Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Catheter-associated Urinary Tract Infections (CAUTIs)
5.2.2 Surgical Site Infections (SSIs)
5.2.3 Central Line-associated Bloodstream Infections (CLABSIs)
5.2.4 Respiratory Infections
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospitals and ICUs
6.2.2 Outpatient Care Centers
6.2.3 Long-term Care Facilities (LTCFs)
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Hospital Acquired Infection Control Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Hospital Acquired Infection Control Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Catheter-associated Urinary Tract Infections (CAUTIs)
9.6.2 Surgical Site Infections (SSIs)
9.6.3 Central Line-associated Bloodstream Infections (CLABSIs)
9.6.4 Respiratory Infections
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospitals and ICUs
9.10.2 Outpatient Care Centers
9.10.3 Long-term Care Facilities (LTCFs)
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Catheter-associated Urinary Tract Infections (CAUTIs)
10.6.2 Surgical Site Infections (SSIs)
10.6.3 Central Line-associated Bloodstream Infections (CLABSIs)
10.6.4 Respiratory Infections
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospitals and ICUs
10.10.2 Outpatient Care Centers
10.10.3 Long-term Care Facilities (LTCFs)
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Catheter-associated Urinary Tract Infections (CAUTIs)
11.6.2 Surgical Site Infections (SSIs)
11.6.3 Central Line-associated Bloodstream Infections (CLABSIs)
11.6.4 Respiratory Infections
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospitals and ICUs
11.10.2 Outpatient Care Centers
11.10.3 Long-term Care Facilities (LTCFs)
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Catheter-associated Urinary Tract Infections (CAUTIs)
12.6.2 Surgical Site Infections (SSIs)
12.6.3 Central Line-associated Bloodstream Infections (CLABSIs)
12.6.4 Respiratory Infections
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospitals and ICUs
12.10.2 Outpatient Care Centers
12.10.3 Long-term Care Facilities (LTCFs)
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Catheter-associated Urinary Tract Infections (CAUTIs)
13.6.2 Surgical Site Infections (SSIs)
13.6.3 Central Line-associated Bloodstream Infections (CLABSIs)
13.6.4 Respiratory Infections
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospitals and ICUs
13.10.2 Outpatient Care Centers
13.10.3 Long-term Care Facilities (LTCFs)
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Hospital Acquired Infection Control Market: Competitive Dashboard
14.2 Global Hospital Acquired Infection Control Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Pfizer
14.3.2 Roche
14.3.3 Merck
14.3.4 Johnson & Johnson
14.3.5 Abott
14.3.6 Bayer
14.3.7 BD
14.3.8 Kimberly-Clark
14.3.9 Nordion
14.3.10 Cepheid
14.3.11 Pfizer